The DOI matches its Crossref record; 248 of the 248 references it cites were found in a registry or an index.
Nanomedicine in cancer therapy: Challenges, opportunities, and clinical applications
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Understanding biophysicochemical interactions at the nano–bio interface
Nel, A. E., Mädler, L., Velegol, D., Xia, T., Hoek, E. M. V., Somasundaran, P., Klaessig, F., Castranova, V., & Thompson, M. (2009) · Nature Materials · doi:10.1038/nmat2442 · Cited by 7,083
Matsumura, Y., & Maeda, H. (1986) · PubMed · Cited by 6,781
Liposomal drug delivery systems: From concept to clinical applications
Allen, T. M., & Cullis, P. R. (2013) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2012.09.037 · Cited by 4,839
Doxil® — The first FDA-approved nano-drug: Lessons learned
Barenholz, Y. (. (2012) · Journal of Controlled Release · doi:10.1016/j.jconrel.2012.03.020 · Cited by 4,792
Trastuzumab emtansine for HER2-positive advanced breast cancer
Verma, S., Miles, D., Gianni, L., Krop, I. E., Welslau, M., Baselga, J., Pegram, M., Oh, D.-Y., Diéras, V., Guardino, E., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1209124 · Cited by 3,834
Delivering nanomedicine to solid tumors
Jain, R. K., & Stylianopoulos, T. (2010) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2010.139 · Cited by 3,180
Lewinski, N., Colvin, V., & Drezek, R. (2008) · Small · doi:10.1002/smll.200700595 · Cited by 2,810
Drug penetration in solid tumours
Minchinton, A. I., & Tannock, I. F. (2006) · Nature reviews. Cancer · doi:10.1038/nrc1893 · Cited by 2,805
Evidence of RNAi in humans from systemically administered siRNA via targeted nanoparticles
Davis, M. E., Zuckerman, J. E., Choi, C. H. J., Seligson, D., Tolcher, A., Alabi, C. A., Yen, Y., Heidel, J. D., & Ribas, A. (2010) · Nature · doi:10.1038/nature08956 · Cited by 2,505
Regulation of transport pathways in tumor vessels: Role of tumor type and microenvironment
Hobbs, S. K., Monsky, W. L., Yuan, F., Roberts, W. G., Griffith, L., Torchilin, V. P., & Jain, R. K. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.8.4607 · Cited by 2,438
Provenzano, P. P., Cuevas, C., Chang, A. E., Goel, V. K., Von Hoff, D. D., & Hingorani, S. R. (2012) · Cancer Cell · doi:10.1016/j.ccr.2012.01.007 · Cited by 2,195
Gradishar, W. J., Tjulandin, S., Davidson, N., Shaw, H., Desai, N., Bhar, P., Hawkins, M., & O'Shaughnessy, J. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.04.937 · Cited by 2,153
Polymer conjugates as anticancer nanomedicines
Duncan, R. (2006) · Nature Reviews Cancer · doi:10.1038/nrc1958 · Cited by 1,962
Multifunctional Inorganic Nanoparticles for Imaging, Targeting, and Drug Delivery
Liong, M., Lu, J., Kovochich, M., Xia, T., Ruehm, S. G., Nel, A. E., Tamanoi, F., & Zink, J. I. (2008) · ACS Nano · doi:10.1021/nn800072t · Cited by 1,929
Immunological properties of engineered nanomaterials
Dobrovolskaia, M. A., & McNeil, S. E. (2007) · Nature Nanotechnology · doi:10.1038/nnano.2007.223 · Cited by 1,823
Active targeting schemes for nanoparticle systems in cancer therapeutics
Byrne, J. D., Betancourt, T., & Brannon-Peppas, L. (2008) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2008.08.005 · Cited by 1,731
Targeted polymeric therapeutic nanoparticles: design, development and clinical translation
Kamaly, N., Xiao, Z., Valencia, P. M., Radovic-Moreno, A. F., & Farokhzad, O. C. (2012) · Chemical Society Reviews · doi:10.1039/c2cs15344k · Cited by 1,730
Targeted nanoparticle-aptamer bioconjugates for cancer chemotherapy in vivo
Farokhzad, O. C., Cheng, J., Teply, B. A., Sherifi, I., Jon, S., Kantoff, P. W., Richie, J. P., & Langer, R. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0601755103 · Cited by 1,663
(1989) · PubMed · Cited by 1,639
Strategies to Address Low Drug Solubility in Discovery and Development
Williams, H. D., Trevaskis, N. L., Charman, S. A., Shanker, R. M., Charman, W. N., Pouton, C. W., & Porter, C. J. H. (2013) · Pharmacological Reviews · doi:10.1124/pr.112.005660 · Cited by 1,570
Younes, A., Gopal, A. K., Smith, S. E., Ansell, S. M., Rosenblatt, J. D., Savage, K. J., Ramchandren, R., Bartlett, N. L., Cheson, B. D., de Vos, S., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.38.0410 · Cited by 1,529
Prabhakar, U., Maeda, H., Jain, R. K., Sevick-Muraca, E. M., Zamboni, W., Farokhzad, O. C., Barry, S. T., Gabizon, A., Grodzinski, P., & Blakey, D. C. (2013) · Cancer Research · doi:10.1158/0008-5472.can-12-4561 · Cited by 1,485
Brentuximab Vedotin (SGN-35) for Relapsed CD30-Positive Lymphomas
Younes, A., Bartlett, N. L., Leonard, J. P., Kennedy, D. A., Lynch, C. M., Sievers, E. L., & Forero-Torres, A. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1002965 · Cited by 1,368
Drug targeting to tumors: Principles, pitfalls and (pre-) clinical progress
Lammers, T., Kiessling, F., Hennink, W. E., & Storm, G. (2012) · Journal of Controlled Release · doi:10.1016/j.jconrel.2011.09.063 · Cited by 1,324
Optimizing Liposomes for Delivery of Chemotherapeutic Agents to Solid Tumors
Drummond, D. C., Meyer, O., Hong, K., Kirpotin, D. B., & Papahadjopoulos, D. (1999) · Pharmacological Reviews · doi:10.1016/s0031-6997(24)01426-1 · Cited by 1,263
Colloidal Gold: A Novel Nanoparticle Vector for Tumor Directed Drug Delivery
Paciotti, G. F., Myer, L., Weinreich, D., Goia, D., Pavel, N., McLaughlin, R. E., & Tamarkin, L. (2004) · Drug Delivery · doi:10.1080/10717540490433895 · Cited by 1,185
Desai, N., Trieu, V., Yao, Z., Louie, L., Ci, S., Yang, A., Tao, C., De, T., Beals, B., Dykes, D., et al. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-1634 · Cited by 1,175
Challenges in Development of Nanoparticle-Based Therapeutics
Desai, N. (2012) · The AAPS Journal · doi:10.1208/s12248-012-9339-4 · Cited by 1,173
Du, J.-Z., Du, X.-J., Mao, C.-Q., & Wang, J. (2011) · Journal of the American Chemical Society · doi:10.1021/ja207150n · Cited by 1,172
Hrkach, J., Von Hoff, D., Ali, M. M., Andrianova, E., Auer, J., Campbell, T., De Witt, D., Figa, M., Figueiredo, M., Horhota, A., et al. (2012) · Science Translational Medicine · doi:10.1126/scitranslmed.3003651 · Cited by 1,147
van Furth, R., Cohn, Z. A., Jg, H., Humphrey, J., Spector, W. G., & Langevoort, H. L. (1972) · PubMed Central · Cited by 1,133
Fleige, E., Quadir, M. A., & Haag, R. (2012) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2012.01.020 · Cited by 1,111
Nanoparticles for drug delivery: The need for precision in reporting particle size parameters
Gaumet, M., Vargas, A., Gurny, R., & Delie, F. (2008) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2007.08.001 · Cited by 1,081
Multistage nanoparticle delivery system for deep penetration into tumor tissue
Wong, C., Stylianopoulos, T., Cui, J., Martin, J., Chauhan, V. P., Jiang, W., Popović, Z., Jain, R. K., Bawendi, M. G., & Fukumura, D. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1018382108 · Cited by 1,062
Endocytic mechanisms for targeted drug delivery☆
BAREFORD, L., & SWAAN, P. (2007) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2007.06.008 · Cited by 1,033
Therapeutic targeting of microRNAs: current status and future challenges
Li, Z., & Rana, T. M. (2014) · Nature Reviews Drug Discovery · doi:10.1038/nrd4359 · Cited by 1,033
Nanomedicine(s) under the Microscope
Duncan, R., & Gaspar, R. (2011) · Molecular Pharmaceutics · doi:10.1021/mp200394t · Cited by 981
Davis, M. E. (2009) · Molecular Pharmaceutics · doi:10.1021/mp900015y · Cited by 977
Safety and efficacy of RNAi therapy for transthyretin amyloidosis
Coelho, T., Adams, D., Silva, A., Lozeron, P., Hawkins, P. N., Mant, T., Perez, J., Chiesa, J., Warrington, S., Tranter, E., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1208760 · Cited by 971
Nanotechnology applications in cancer
Nie, S., Xing, Y., Kim, G. J., & Simons, J. W. (2007) · Annual Review of Biomedical Engineering · doi:10.1146/annurev.bioeng.9.060906.152025 · Cited by 952
Antibody–Drug Conjugates: An Emerging Concept in Cancer Therapy
Chari, R. V. J., Miller, M. L., & Widdison, W. C. (2014) · Angewandte Chemie International Edition · doi:10.1002/anie.201307628 · Cited by 930
Theranostic Nanoshells: From Probe Design to Imaging and Treatment of Cancer
Bardhan, R., Lal, S., Joshi, A., & Halas, N. J. (2011) · Accounts of Chemical Research · doi:10.1021/ar200023x · Cited by 917
Approval summary: gemtuzumab ozogamicin in relapsed acute myeloid leukemia.
Bross, P. F., Beitz, J. G., Chen, G., Chen, X., Duffy, E. J., Kieffer, L. V., Roy, S., Sridhara, R. N., Rahman, A., Williams, G., et al. (2001) · PubMed · Cited by 855
Progress of drug-loaded polymeric micelles into clinical studies
Cabral, H., & Kataoka, K. (2014) · Journal of Controlled Release · doi:10.1016/j.jconrel.2014.06.042 · Cited by 837
RNA interference in the clinic: challenges and future directions
Pecot, C. V., Calin, G. A., Coleman, R. L., Lopez-Berestein, G., & Sood, A. K. (2011) · Nature Reviews Cancer · doi:10.1038/nrc2966 · Cited by 820
Effects of nanomaterial physicochemical properties on in vivo toxicity
Aillon, K. L., Xie, Y., El-Gendy, N., Berkland, C. J., & Forrest, M. L. (2009) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2009.03.010 · Cited by 811
Nanomedicine: Developing smarter therapeutic and diagnostic modalities☆
FAROKHZAD, O., & LANGER, R. (2006) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2006.09.011 · Cited by 800
Protein nanoparticles as drug carriers in clinical medicine
Hawkins, M. J., Soon-Shiong, P., & Desai, N. (2008) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2007.08.044 · Cited by 779
Anti-HER2 immunoliposomes: enhanced efficacy attributable to targeted delivery.
Park, J. W., Hong, K., Kirpotin, D. B., Colbern, G. T., Shalaby, R., Baselga, J. M., Shao, Y. Y., Nielsen, U. B., Marks, J. D., Moore, D. H., et al. (2002) · Clinical Cancer Research · Cited by 766
Burris, H. A., Rugo, H. S., Vukelja, S. J., Vogel, C. L., Borson, R. A., Limentani, S., Tan-Chiu, E., Krop, I. E., Michaelson, R. A., Girish, S., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.29.5865 · Cited by 764
Sayes, C. M., Reed, K. L., & Warheit, D. B. (2007) · Toxicological Sciences · doi:10.1093/toxsci/kfm018 · Cited by 762
Socinski, M. A., Bondarenko, I., Karaseva, N. A., Makhson, A. M., Vynnychenko, I., Okamoto, I., Hon, J. K., Hirsh, V., Bhar, P., Zhang, H., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.39.5848 · Cited by 756
Meyers, P. A., Schwartz, C. L., Krailo, M. D., Healey, J. H., Bernstein, M. L., Betcher, D., Ferguson, W. S., Gebhardt, M. C., Goorin, A. M., Harris, M., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2008.14.0095 · Cited by 752
Needham, D., Anyarambhatla, G., Kong, G., & Dewhirst, M. W. (2000) · PubMed · Cited by 746
Detection and characterization of engineered nanoparticles in food and the environment
Tiede, K., Boxall, A. B. A., Tear, S. P., Lewis, J., David, H., & Hassellöv, M. (2008) · Food Additives & Contaminants: Part A · doi:10.1080/02652030802007553 · Cited by 737
Phase I and Pharmacokinetic Studies of CYT-6091, a Novel PEGylated Colloidal Gold-rhTNF Nanomedicine
Libutti, S. K., Paciotti, G. F., Byrnes, A. A., Alexander, H. R., Gannon, W. E., Walker, M., Seidel, G. D., Yuldasheva, N., & Tamarkin, L. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-0978 · Cited by 710
The journey of a drug-carrier in the body: An anatomo-physiological perspective
Bertrand, N., & Leroux, J.-C. (2012) · Journal of Controlled Release · doi:10.1016/j.jconrel.2011.09.098 · Cited by 707
Tabernero, J., Shapiro, G. I., LoRusso, P. M., Cervantes, A., Schwartz, G. K., Weiss, G. J., Paz-Ares, L., Cho, D. C., Infante, J. R., Alsina, M., et al. (2013) · Cancer Discovery · doi:10.1158/2159-8290.cd-12-0429 · Cited by 698
Vasey, P. A., Kaye, S. B., Morrison, R. A., Twelves, C. J., Wilson, P., Duncan, R., Thomson, A. H., Murray, L. S., Hilditch, T. E., Murray, T., et al. (1999) · PubMed · Cited by 689
Therapeutic EphA2 Gene Targeting In vivo Using Neutral Liposomal Small Interfering RNA Delivery
Landen, C. N., Chavez-Reyes, A., Bucana, C., Schmandt, R., Deavers, M. T., Lopez-Berestein, G., & Sood, A. K. (2005) · Cancer Research · doi:10.1158/0008-5472.can-05-0530 · Cited by 675
Batist, G., Ramakrishnan, G., Rao, C. S., Chandrasekharan, A., Gutheil, J., Guthrie, T., Shah, P., Khojasteh, A., Nair, M. K., Hoelzer, K., et al. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.5.1444 · Cited by 669
SMANCS and polymer-conjugated macromolecular drugs: advantages in cancer chemotherapy
Maeda, H. (2001) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(00)00134-4 · Cited by 662
Brain drug delivery of small molecules using immunoliposomes
Huwyler, J., Wu, D., & Pardridge, W. M. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.24.14164 · Cited by 656
Self-citationMuggia, F. M., Hainsworth, J. D., Jeffers, S., Miller, P., Groshen, S., Tan, M., Roman, L., Uziely, B., Muderspach, L., Garcia, A., et al. (1997) · Journal of Clinical Oncology · doi:10.1200/jco.1997.15.3.987 · Cited by 647
Multimodal silica nanoparticles are effective cancer-targeted probes in a model of human melanoma
Benezra, M., Penate-Medina, O., Zanzonico, P. B., Schaer, D., Ow, H., Burns, A., DeStanchina, E., Longo, V., Herz, E., Iyer, S., et al. (2011) · Journal of Clinical Investigation · doi:10.1172/jci45600 · Cited by 645
Phase I clinical trial and pharmacokinetic evaluation of NK911, a micelle-encapsulated doxorubicin
Matsumura, Y., Hamaguchi, T., Ura, T., Muro, K., Yamada, Y., Shimada, Y., Shirao, K., Okusaka, T., Ueno, H., Ikeda, M., et al. (2004) · British Journal of Cancer · doi:10.1038/sj.bjc.6602204 · Cited by 623
Inorganic nanoparticles for cancer imaging and therapy
Huang, H.-C., Barua, S., Sharma, G., Dey, S. K., & Rege, K. (2011) · Journal of Controlled Release · doi:10.1016/j.jconrel.2011.06.004 · Cited by 618
Multifunctional and stimuli-sensitive pharmaceutical nanocarriers
Torchilin, V. (2009) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2008.09.026 · Cited by 583
Harrington, K. J., Mohammadtaghi, S., Uster, P. S., Glass, D. M., Peters, A. M., Vile, R. G., & Stewart, J. S. W. (2001) · PubMed · Cited by 575
Intravenous delivery of a multi-mechanistic cancer-targeted oncolytic poxvirus in humans
Breitbach, C. J., Burke, J., Jonker, D., Stephenson, J., Haas, A. R., Chow, L. Q. M., Nieva, J., Hwang, T.-H., Moon, A., Patt, R., et al. (2011) · Nature · doi:10.1038/nature10358 · Cited by 551
Ahmed, F., Pakunlu, R. I., Brannan, A., Bates, F., Minko, T., & Discher, D. E. (2006) · Journal of Controlled Release · doi:10.1016/j.jconrel.2006.07.012 · Cited by 548
Nanomedicines: addressing the scientific and regulatory gap
Tinkle, S., McNeil, S. E., Mühlebach, S., Bawa, R., Borchard, G., Barenholz, Y. (., Tamarkin, L., & Desai, N. (2014) · Annals of the New York Academy of Sciences · doi:10.1111/nyas.12403 · Cited by 546
Lee, K. S., Chung, H. C., Im, S. A., Park, Y. H., Kim, C. S., Kim, S.-B., Rha, S. Y., Lee, M. Y., & Ro, J. (2008) · Breast Cancer Research and Treatment · doi:10.1007/s10549-007-9591-y · Cited by 541
Drug Release from Electric-Field-Responsive Nanoparticles
Ge, J., Neofytou, E., Cahill, T. J., Beygui, R. E., & Zare, R. N. (2012) · ACS Nano · doi:10.1021/nn203430m · Cited by 534
Glantz, M., Jaeckle, K. A., Chamberlain, M. C., Phuphanich, S., Recht, L. D., Swinnen, L. J., Maria, B., LaFollette, S., Schumann, G. B., Cole, B. F., et al. (1999) · PubMed · Cited by 529
Nanotheranostics for personalized medicine
Mura, S., & Couvreur, P. (2012) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2012.06.006 · Cited by 527
Biodegradable nanoparticles for cytosolic delivery of therapeutics
VASIR, J., & LABHASETWAR, V (2007) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2007.06.003 · Cited by 526
Park, B.-H., Hwang, T., Liu, T.-C., Sze, D. Y., Kim, J.-S., Kwon, H.-C., Oh, S. Y., Han, S.-Y., Yoon, J.-H., Hong, S.-H., et al. (2008) · The Lancet Oncology · doi:10.1016/s1470-2045(08)70107-4 · Cited by 521
Dhar, S., Kolishetti, N., Lippard, S. J., & Farokhzad, O. C. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1011379108 · Cited by 513
Combining two strategies to improve perfusion and drug delivery in solid tumors
Stylianopoulos, T., & Jain, R. K. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1318415110 · Cited by 508
Interactions of nanomaterials and biological systems: Implications to personalized nanomedicine
Zhang, X.-Q., Xu, X., Bertrand, N., Pridgen, E., Swami, A., & Farokhzad, O. C. (2012) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2012.08.005 · Cited by 487
First microRNA mimic enters clinic
Bouchie, A. (2013) · Nature Biotechnology · doi:10.1038/nbt0713-577 · Cited by 472
Morschhauser, F., Radford, J., Van Hoof, A., Vitolo, U., Soubeyran, P., Tilly, H., Huijgens, P. C., Kolstad, A., d’Amore, F., Diaz, M. G., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2008.17.2015 · Cited by 460
Manzoor, A. A., Lindner, L. H., Landon, C. D., Park, J.-Y., Simnick, A. J., Dreher, M. R., Das, S., Hanna, G., Park, W., Chilkoti, A., et al. (2012) · Cancer Research · doi:10.1158/0008-5472.can-12-1683 · Cited by 459
Clinical trial results with oncolytic virotherapy: a century of promise, a decade of progress
Liu, T.-C., Galanis, E., & Kirn, D. (2007) · Nature Clinical Practice Oncology · doi:10.1038/ncponc0736 · Cited by 450
Gill, P. S., Wernz, J., Scadden, D. T., Cohen, P., Mukwaya, G. M., von Roenn, J. H., Jacobs, M., Kempin, S., Silverberg, I., Gonzales, G., et al. (1996) · Journal of Clinical Oncology · doi:10.1200/jco.1996.14.8.2353 · Cited by 438
Hepatic Drug Targeting: Phase I Evaluation of Polymer-Bound Doxorubicin
Seymour, L. W., Ferry, D. R., Anderson, D., Hesslewood, S., Julyan, P. J., Poyner, R., Doran, J., Young, A., Burtles, S. S., & Kerr, D. J. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.20.6.1668 · Cited by 435
Development of in vitro systems for nanotoxicology: methodological considerations
Stone, V., Johnston, H., & Schins, R. P. F. (2009) · Critical Reviews in Toxicology · doi:10.1080/10408440903120975 · Cited by 427
Szebeni, J., Muggia, F., Gabizon, A., & Barenholz, Y. (2011) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2011.06.017 · Cited by 423
Rapoport, N., Nam, K.-H., Gupta, R., Gao, Z., Mohan, P., Payne, A., Todd, N., Liu, X., Kim, T., Shea, J., et al. (2011) · Journal of Controlled Release · doi:10.1016/j.jconrel.2011.01.022 · Cited by 423
Juweid, M. E., Neumann, R. D., Paik, C. H., Pérez-Bacete, M., Sato, J., van Osdol, W. W., & Weinstein, J. N. (1992) · PubMed · Cited by 406
Targeted and armed oncolytic poxviruses: a novel multi-mechanistic therapeutic class for cancer
Kirn, D. H., & Thorne, S. H. (2009) · Nature Reviews Cancer · doi:10.1038/nrc2545 · Cited by 402
Ligand-targeted particulate nanomedicines undergoing clinical evaluation: Current status
van der Meel, R., Vehmeijer, L. J. C., Kok, R. J., Storm, G., & van Gaal, E. V. B. (2013) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2013.08.012 · Cited by 398
Plummer, R., Wilson, R. H., Calvert, H., Boddy, A. V., Griffin, M., Sludden, J., Tilby, M. J., Eatock, M., Pearson, D. G., Ottley, C. J., et al. (2011) · British Journal of Cancer · doi:10.1038/bjc.2011.6 · Cited by 390
Stimuli-responsive polymers and nanomaterials for gene delivery and imaging applications
Shim, M. S., & Kwon, Y. J. (2012) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2012.01.018 · Cited by 384
Mamot, C., Drummond, D. C., Noble, C. O., Kallab, V., Guo, Z., Hong, K., Kirpotin, D. B., & Park, J. W. (2005) · Cancer Research · doi:10.1158/0008-5472.can-05-1093 · Cited by 382
Nanoscale Radiotherapy with Hafnium Oxide Nanoparticles
Maggiorella, L., Barouch, G., Devaux, C., Pottier, A., Deutsch, E., Bourhis, J., Borghi, E., & Levy, L. (2012) · Future Oncology · doi:10.2217/fon.12.96 · Cited by 373
UV and Near-IR Triggered Release from Polymeric Nanoparticles
Fomina, N., McFearin, C., Sermsakdi, M., Edigin, O., & Almutairi, A. (2010) · Journal of the American Chemical Society · doi:10.1021/ja102595j · Cited by 362
Recent progress in nanomedicine: therapeutic, diagnostic and theranostic applications
Rizzo, L. Y., Theek, B., Storm, G., Kiessling, F., & Lammers, T. (2013) · Current Opinion in Biotechnology · doi:10.1016/j.copbio.2013.02.020 · Cited by 336
Confirming the RNAi-mediated mechanism of action of siRNA-based cancer therapeutics in mice
Judge, A. D., Robbins, M., Tavakoli, I., Levi, J., Hu, L., Fronda, A., Ambegia, E., McClintock, K., & MacLachlan, I. (2009) · Journal of Clinical Investigation · doi:10.1172/jci37515 · Cited by 336
Stimuli-sensitive nanopreparations for combination cancer therapy
Jhaveri, A., Deshpande, P., & Torchilin, V. (2014) · Journal of Controlled Release · doi:10.1016/j.jconrel.2014.05.002 · Cited by 334
Oncolytic viruses in cancer therapy
Vähä-Koskela, M. J. V., Heikkilä, J. E., & Hinkkanen, A. E. (2007) · Cancer Letters · doi:10.1016/j.canlet.2007.02.002 · Cited by 333
Multifunctional Micellar Nanomedicine for Cancer Therapy
Blanco, E., Kessinger, C. W., Sumer, B. D., & Gao, J. (2009) · Experimental Biology and Medicine · doi:10.3181/0808-mr-250 · Cited by 332
Squalenoyl Nanomedicines as Potential Therapeutics
Couvreur, P., Stella, B., Reddy, L. H., Hillaireau, H., Dubernet, C., Desmaële, D., Lepêtre-Mouelhi, S., Rocco, F., Dereuddre-Bosquet, N., Clayette, P., et al. (2006) · Nano Letters · doi:10.1021/nl061942q · Cited by 329
Dinndorf, P. A., Gootenberg, J., Cohen, M. H., Keegan, P., & Pazdur, R. (2007) · The Oncologist · doi:10.1634/theoncologist.12-8-991 · Cited by 324
Feldman, E. J., Lancet, J. E., Kolitz, J. E., Ritchie, E. K., Roboz, G. J., List, A. F., Allen, S. L., Asatiani, E., Mayer, L. D., Swenson, C., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.30.5961 · Cited by 310
Ultrasound triggered release of cisplatin from liposomes in murine tumors
Schroeder, A., Honen, R., Turjeman, K., Gabizon, A., Kost, J., & Barenholz, Y. (2009) · Journal of Controlled Release · doi:10.1016/j.jconrel.2009.03.007 · Cited by 305
Gaspar, R., & Duncan, R. (2009) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2009.06.003 · Cited by 304
Seymour (2009) · International Journal of Oncology · doi:10.3892/ijo_00000293 · Cited by 304
Valle, J. W., Armstrong, A., Newman, C., Alakhov, V., Pietrzynski, G., Brewer, J., Campbell, S., Corrie, P., Rowinsky, E. K., & Ranson, M. (2011) · Investigational New Drugs · doi:10.1007/s10637-010-9399-1 · Cited by 303
Physico-chemical features of engineered nanoparticles relevant to their toxicity
Fubini, B., Ghiazza, M., & Fenoglio, I. (2010) · Nanotoxicology · doi:10.3109/17435390.2010.509519 · Cited by 297
Shear-stress sensitive lenticular vesicles for targeted drug delivery
Holme, M. N., Fedotenko, I. A., Abegg, D., Althaus, J., Babel, L., Favarger, F., Reiter, R., Tanasescu, R., Zaffalon, P.-L., Ziegler, A., et al. (2012) · Nature Nanotechnology · doi:10.1038/nnano.2012.84 · Cited by 289
(2004) · The Women's Oncology Review · doi:10.3109/14733400410001727592 · Cited by 288
Oncolytic viral therapies – the clinical experience
Aghi, M., & Martuza, R. L. (2005) · Oncogene · doi:10.1038/sj.onc.1209037 · Cited by 288
Meerum Terwogt, J. M., ten Bokkel Huinink, W. W., Schellens, J. H., Schot, M., Mandjes, I. A., Zurlo, M. G., Rocchetti, M., Rosing, H., Koopman, F. J., & Beijnen, J. H. (2001) · Anti-Cancer Drugs · doi:10.1097/00001813-200104000-00003 · Cited by 279
Rijcken, C. J., Snel, C. J., Schiffelers, R. M., van Nostrum, C. F., & Hennink, W. E. (2007) · Biomaterials · doi:10.1016/j.biomaterials.2007.08.047 · Cited by 278
McDonagh, C. F., Huhalov, A., Harms, B. D., Adams, S., Paragas, V., Oyama, S., Zhang, B., Luus, L., Overland, R., Nguyen, S., et al. (2012) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-11-0820 · Cited by 278
Best Practices in Cancer Nanotechnology: Perspective from NCI Nanotechnology Alliance
Zamboni, W. C., Torchilin, V., Patri, A. K., Hrkach, J., Stern, S., Lee, R., Nel, A., Panaro, N. J., & Grodzinski, P. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-2938 · Cited by 275
Gaillard, P. J., Appeldoorn, C. C. M., Dorland, R., van Kregten, J., Manca, F., Vugts, D. J., Windhorst, B., van Dongen, G. A. M. S., de Vries, H. E., Maussang, D., et al. (2014) · PLoS ONE · doi:10.1371/journal.pone.0082331 · Cited by 273
Nanoparticle delivery systems for cancer therapy: advances in clinical and preclinical research
Egusquiaguirre, S. P., Igartua, M., Hernández, R. M., & Pedraz, J. L. (2012) · Clinical and Translational Oncology · doi:10.1007/s12094-012-0766-6 · Cited by 268
Wang, Y.-C., Wang, F., Sun, T.-M., & Wang, J. (2011) · Bioconjugate Chemistry · doi:10.1021/bc200139n · Cited by 268
Horning, S. J., Younes, A., Jain, V., Kroll, S., Lucas, J., Podoloff, D., & Goris, M. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.07.040 · Cited by 258
Targeting Dendritic Cells with Antigen-Containing Liposomes
van Broekhoven, C. L., Parish, C. R., Demangel, C., Britton, W. J., & Altin, J. G. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-0138 · Cited by 256
Matsumura, Y., Gotoh, M., Muro, K., Yamada, Y., Shirao, K., Shimada, Y., Okuwa, M., Matsumoto, S., Miyata, Y., Ohkura, H., et al. (2004) · Annals of Oncology · doi:10.1093/annonc/mdh092 · Cited by 253
Effective anti-tumor activity of oxaliplatin encapsulated in transferrin–PEG-liposome
Suzuki, R., Takizawa, T., Kuwata, Y., Mutoh, M., Ishiguro, N., Utoguchi, N., Shinohara, A., Eriguchi, M., Yanagie, H., & Maruyama, K. (2008) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2007.06.010 · Cited by 250
Mamot, C., Ritschard, R., Wicki, A., Stehle, G., Dieterle, T., Bubendorf, L., Hilker, C., Deuster, S., Herrmann, R., & Rochlitz, C. (2012) · The Lancet Oncology · doi:10.1016/s1470-2045(12)70476-x · Cited by 244
Self-citationWestphal, M., Ylä-Herttuala, S., Martin, J., Warnke, P., Menei, P., Eckland, D., Kinley, J., Kay, R., & Ram, Z. (2013) · The Lancet Oncology · doi:10.1016/s1470-2045(13)70274-2 · Cited by 241
Kato, K., Chin, K., Yoshikawa, T., Yamaguchi, K., Tsuji, Y., Esaki, T., Sakai, K., Kimura, M., Hamaguchi, T., Shimada, Y., et al. (2012) · Investigational New Drugs · doi:10.1007/s10637-011-9709-2 · Cited by 237
Phase I Study of a Systemically Delivered p53 Nanoparticle in Advanced Solid Tumors
Senzer, N., Nemunaitis, J., Nemunaitis, D., Bedell, C., Edelman, G., Barve, M., Nunan, R., Pirollo, K. F., Rait, A., & Chang, E. H. (2013) · Molecular Therapy · doi:10.1038/mt.2013.32 · Cited by 236
Antibody‐Drug Conjugates for the Treatment of Cancer
Flygare, J. A., Pillow, T. H., & Aristoff, P. (2013) · Chemical Biology & Drug Design · doi:10.1111/cbdd.12085 · Cited by 232
Weiss, G. J., Chao, J., Neidhart, J. D., Ramanathan, R. K., Bassett, D., Neidhart, J. A., Choi, C. H. J., Chow, W., Chung, V., Forman, S. J., et al. (2013) · Investigational New Drugs · doi:10.1007/s10637-012-9921-8 · Cited by 230
pH-triggered intracellular release from actively targeting polymer micelles
Guo, X., Shi, C., Wang, J., Di, S., & Zhou, S. (2013) · Biomaterials · doi:10.1016/j.biomaterials.2013.02.071 · Cited by 225
Therapeutic Nanoparticles to Combat Cancer Drug Resistance
Hu, C.-M., & Zhang, L. (2009) · Current Drug Metabolism · doi:10.2174/138920009790274540 · Cited by 223
Hawe, A., Hulse, W. L., Jiskoot, W., & Forbes, R. T. (2011) · Pharmaceutical Research · doi:10.1007/s11095-011-0460-3 · Cited by 221
Barraud, L., Merle, P., Soma, E., Lefrançois, L., Guerret, S., Chevallier, M., Dubernet, C., Couvreur, P., Trépo, C., & Vitvitski, L. (2005) · Journal of Hepatology · doi:10.1016/j.jhep.2004.12.035 · Cited by 217
Rademaker-Lakhai, J. M., Terret, C., Howell, S. B., Baud, C. M., de Boer, R. F., Pluim, D., Beijnen, J. H., Schellens, J. H. M., & Droz, J.-P. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-03-0315 · Cited by 214
Batist, G., Gelmon, K. A., Chi, K. N., Miller, W. H., Chia, S. K. L., Mayer, L. D., Swenson, C. E., Janoff, A. S., & Louie, A. C. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-0515 · Cited by 213
Maksimenko, A., Dosio, F., Mougin, J., Ferrero, A., Wack, S., Reddy, L. H., Weyn, A.-A., Lepeltier, E., Bourgaux, C., Stella, B., et al. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1313459110 · Cited by 212
Engineered nanomaterial uptake and tissue distribution: from cell to organism
Huwyler, J., Kettiger, H., Schipanski, A., & Wick, P. (2013) · International Journal of Nanomedicine · doi:10.2147/ijn.s49770 · Cited by 210
Self-citationThe role of nanoparticle size in hemocompatibility
Mayer, A., Vadon, M., Rinner, B., Novak, A., Wintersteiger, R., & Fröhlich, E. (2009) · Toxicology · doi:10.1016/j.tox.2009.01.015 · Cited by 209
Kirpotin, D., Hong, K., Mullah, N., Papahadjopoulos, D., & Zalipsky, S. (1996) · FEBS Letters · doi:10.1016/0014-5793(96)00521-2 · Cited by 206
Nanopharmacy: Inorganic nanoscale devices as vectors and active compounds
Rivera Gil, P., Hühn, D., del Mercato, L. L., Sasse, D., & Parak, W. J. (2010) · Pharmacological Research · doi:10.1016/j.phrs.2010.01.009 · Cited by 202
O'Brien, S., Schiller, G., Lister, J., Damon, L., Goldberg, S., Aulitzky, W., Ben-Yehuda, D., Stock, W., Coutre, S., Douer, D., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.46.2309 · Cited by 196
Resnik, D. B., & Tinkle, S. S. (2007) · Nanomedicine · doi:10.2217/17435889.2.3.345 · Cited by 192
Villard, L., Romer, A., Marincek, N., Brunner, P., Koller, M. T., Schindler, C., Ng, Q. K. T., Mäcke, H. R., Müller-Brand, J., Rochlitz, C., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.37.2151 · Cited by 189
Lu, C., Stewart, D. J., Lee, J. J., Ji, L., Ramesh, R., Jayachandran, G., Nunez, M. I., Wistuba, I. I., Erasmus, J. J., Hicks, M. E., et al. (2012) · PLoS ONE · doi:10.1371/journal.pone.0034833 · Cited by 184
Tumor targeting using liposomal antineoplastic drugs
Huwyler, J. (2008) · International Journal of Nanomedicine · doi:10.2147/ijn.s1253 · Cited by 182
Self-citationPolymer–drug conjugates: towards a novel approach for the treatment of endrocine-related cancer
Duncan, R., Vicent, M. J., Greco, F., & Nicholson, R. I. (2005) · Endocrine-Related Cancer · doi:10.1677/erc.1.01045 · Cited by 179
Patel, N. R., Rathi, A., Mongayt, D., & Torchilin, V. P. (2011) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2011.05.082 · Cited by 173
Maruyama, K., Takahashi, N., Tagawa, T., Nagaike, K., & Iwatsuru, M. (1997) · FEBS Letters · doi:10.1016/s0014-5793(97)00905-8 · Cited by 170
Liu, C., Liu, F., Feng, L., Li, M., Zhang, J., & Zhang, N. (2013) · Biomaterials · doi:10.1016/j.biomaterials.2012.12.038 · Cited by 168
ProLindac™ (AP5346): A review of the development of an HPMA DACH platinum Polymer Therapeutic
Nowotnik, D. P., & Cvitkovic, E. (2009) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2009.06.004 · Cited by 167
Phase I Study of Aerosolized SLIT Cisplatin in the Treatment of Patients with Carcinoma of the Lung
Wittgen, B. P. H., Kunst, P. W. A., van der Born, K., van Wijk, A. W., Perkins, W., Pilkiewicz, F. G., Perez-Soler, R., Nicholson, S., Peters, G. J., & Postmus, P. E. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-1480 · Cited by 166
Tardi, P. G., CHOICE, E., Masin, D., Redelmeier, T. E., Bally, M. B., & Madden, T. D. (2000) · PubMed · Cited by 161
Ko, A. H., Tempero, M. A., Shan, Y.-S., Su, W.-C., Lin, Y.-L., Dito, E., Ong, A., Wang, Y.-W., Yeh, C. G., & Chen, L.-T. (2013) · British Journal of Cancer · doi:10.1038/bjc.2013.408 · Cited by 160
Chan, S. Y. T., Davidson, N. G. P., Juozaitytė, E., et al. (2004) · Annals of Oncology · doi:10.1093/annonc/mdh393 · Cited by 155
Revival of the abandoned therapeutic wortmannin by nanoparticle drug delivery
Karve, S., Werner, M. E., Sukumar, R., Cummings, N. D., Copp, J. A., Wang, E. C., Li, C., Sethi, M., Chen, R. C., Pacold, M. E., et al. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1120508109 · Cited by 154
Phase I clinical and pharmacokinetic trial of dextran conjugated doxorubicin (AD-70, DOX-OXD)
Danhauser-riedl, S., Hausmann, E., Schick, H.-D., Bender, R., Dietzfelbinger, H., Rastetter, J., & Hanauske, A.-R. (1993) · Investigational New Drugs · doi:10.1007/bf00874153 · Cited by 152
FDA's Approach to Regulation of Products of Nanotechnology
Hamburg, M. A. (2012) · Science · doi:10.1126/science.1205441 · Cited by 152
Nanoconjugation modulates the trafficking and mechanism of antibody induced receptor endocytosis
Bhattacharyya, S., Bhattacharya, R., Curley, S. A., McNiven, M. A., & Mukherjee, P. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1006507107 · Cited by 147
Phase I/II study of pegylated arginine deiminase (ADI-PEG 20) in patients with advanced melanoma
Ott, P. A., Carvajal, R. D., Pandit-Taskar, N., Jungbluth, A. A., Hoffman, E. W., Wu, B.-W., Bomalaski, J. S., Venhaus, R., Pan, L., Old, L. J., et al. (2013) · Investigational New Drugs · doi:10.1007/s10637-012-9862-2 · Cited by 146
Rodriguez, M. A., Pytlík, R., Kozák, T., Chhanabhai, M., Gascoyne, R. D., Lu, B., Deitcher, S. R., & Winter, J. N. (2009) · Cancer · doi:10.1002/cncr.24359 · Cited by 145
Hamaguchi, T., Doi, T., Nakajima, T. E., Kato, K., Yamada, Y., Shimada, Y., Fuse, N., Ohtsu, A., Matsumoto, S.-I., Takanashi, M., et al. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-0387 · Cited by 145
Xu, X., Wang, L., Xu, H.-Q., Huang, X., Qian, Y.-D., & Xiang, J. (2013) · Asian Pacific Journal of Cancer Prevention · doi:10.7314/apjcp.2013.14.4.2591 · Cited by 144
Sarris, A. H., Hagemeister, F. B., Romaguera, J. E., Rodríguez, M., McLaughlin, P. J., Tsimberidou, A. M., Medeiros, L. J., Samuels, B. I., Pate, O., Oholendt, M. S., et al. (2000) · Annals of Oncology · doi:10.1023/a:1008348010437 · Cited by 143
Dragovich, T., Mendelson, D. S., Kurtin, S. E., Richardson, K., Hoff, D. D. V., & Hoos, A. (2006) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-006-0235-4 · Cited by 142
Awada, A. H., Bondarenko, I., Bonneterre, J. M., Nowara, E., Ferrero, J.-M., Bakshi, A. V., Wilke, C., & Piccart, M. J. (2014) · Annals of Oncology · doi:10.1093/annonc/mdu025 · Cited by 142
Obata, Y., Tajima, S., & Takeoka, S. (2009) · Journal of Controlled Release · doi:10.1016/j.jconrel.2009.10.023 · Cited by 140
Strumberg, D., Schultheis, B. S., Traugott, U., Vank, C., Santel, A., Keil, O., Giese, K., Kaufmann, J., & Drevs, J. (2011) · International Journal of Clinical Pharmacology and Therapeutics · doi:10.5414/cpp50076 · Cited by 137
Extravasation of macromolecules
Takakura, Y., Mahato, R. I., & Hashida, M. (1998) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(98)00006-4 · Cited by 134
Curative Properties of Noninternalizing Antibody–Drug Conjugates Based on Maytansinoids
Perrino, E., Steiner, M., Krall, N., Bernardes, G. J. L., Pretto, F., Casi, G., & Neri, D. (2014) · Cancer Research · doi:10.1158/0008-5472.can-13-2990 · Cited by 130
Mifamurtide: A Review of its Use in the Treatment of Osteosarcoma
Frampton, J. E. (2010) · Pediatric Drugs · doi:10.2165/11204910-000000000-00000 · Cited by 128
Liposomal Anthracyclines in Metastatic Breast Cancer: Clinical Update
Rivera, E. (2003) · The Oncologist · doi:10.1634/theoncologist.8-2004-3 · Cited by 128
Novel RNA oligonucleotide improves liver function and inhibits liver carcinogenesis in vivo
Reebye, V., Sætrom, P., Mintz, P. J., Huang, K., Swiderski, P. M., Peng, L., Liu, C., Liu, X., Lindkær-Jensen, S., Zacharoulis, D., et al. (2013) · Hepatology · doi:10.1002/hep.26669 · Cited by 126
By-passing of P-glycoprotein Using Immunoliposomes
Huwyler, J., Cerletti, A., Fricker, G., Eberlé, A. N., & Drewe, J. (2002) · Journal of drug targeting · doi:10.1080/10611860290007559 · Cited by 125
Self-citationBissett, D., Cassidy, J., Bono, J. S. D., et al. (2004) · British Journal of Cancer · doi:10.1038/sj.bjc.6601922 · Cited by 125
Sabbatini, P. J., Aghajanian, C. A., Dizon, D. S., Anderson, S., Dupont, J., Brown, J. V., Peters, W. A., Jacobs, A. D., Mehdi, A., Rivkin, S. E., et al. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.12.043 · Cited by 125
National survey on the effect of oncology drug shortages on cancer care
McBride, A., Holle, L. M., Westendorf-Overley, C., Sidebottom, M., Griffith, N. L., Muller, R. J., & Hoffman, J. M. (2013) · American Journal of Health-System Pharmacy · doi:10.2146/ajhp120563 · Cited by 123
Roy, A. C., Park, S. R., Cunningham, D., Kang, Y., Chao, Y., Chen, L., Rees, C., Lim, H. Y., Tabernero, J. M., Ramos, F. J., et al. (2013) · Annals of Oncology · doi:10.1093/annonc/mdt002 · Cited by 123
Koshkaryev, A., Sawant, R. R., Deshpande, M., & Torchilin, V. P. (2012) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2012.08.009 · Cited by 122
(2004) · The Women s Oncology Review · doi:10.1080/14733400410001727592 · Cited by 120
Andtbacka, R. H. I., Collichio, F. A., AMATRUDA, T. T., Senzer, N. N., Chesney, J. A., Delman, K. A., S̄pitler, L. E., Puzanov, I. J., Doleman, S., Ye, Y., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2013.31.15_suppl.lba9008 · Cited by 119
He, Y., Zeng, Q., Drenning, S. D., Melhem, M. F., Tweardy, D. J., Huang, L., & Grandis, J. R. (1998) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/90.14.1080 · Cited by 108
Phase II study of liposomal cisplatin (SPI-77) in platinum-sensitive recurrences of ovarian cancer.
Seetharamu, N., Kim, E., Höchster, H. S., Martin, F., & Muggia, F. M. (2010) · PubMed · Cited by 107
Homsi, J., Simon, G. R., Garrett, C. R., Springett, G. M., Conti, R. C. D., Chiappori, A., Münster, P. N., Burton, M. K., Stromatt, S. C., Allievi, C., et al. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-2821 · Cited by 103
Comparison of liposomal cisplatin versus cisplatin in non-squamous cell non-small-cell lung cancer
Stathopoulos, G. P., Antoniou, D., Dimitroulis, J., Stathopoulos, J., Marosis, K., & Michalopoulou, P. (2011) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-011-1572-5 · Cited by 102
Semple, S. C., Leone, R., Wang, J., Leng, E. C., Klimuk, S. K., Eisenhardt, M. L., Yuan, Z.-N., Edwards, K., Maurer, N., Hope, M. J., et al. (2005) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.20332 · Cited by 101
WICKI, A. N., Rochlitz, C. F., Orleth, A., Ritschard, R., Albrecht, I., Herrmann, R., Christofori, G., & Mamot, C. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-1102 · Cited by 101
Self-citationFunctional and morphological studies of protein transcytosis in continuous endothelia
Predescu, D. N., Vogel, S. M., & Malik, A. B. (2004) · American Journal of Physiology-Lung Cellular and Molecular Physiology · doi:10.1152/ajplung.00075.2004 · Cited by 100
Yurkovetskiy, A., & Fram, R. J. (2009) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2009.01.007 · Cited by 100
Poon, R. T. P., & Borys, N. (2011) · Future Oncology · doi:10.2217/fon.11.73 · Cited by 100
Role of chitosan nanoparticles in the oral absorption of Gemcitabine
Derakhshandeh, K., & Ahmed, S. F. (2012) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2012.08.008 · Cited by 99
Improved anti‐tumor activity of stabilized anthracycline polymeric micelle formulation, NC‐6300
Harada, M., Bobe, I., Saito, H., Shibata, N., Tanaka, R., Hayashi, T., & Kato, Y. (2010) · Cancer Science · doi:10.1111/j.1349-7006.2010.01745.x · Cited by 99
Gabizon, A., Tzemach, D., Horowitz, A. T., Shmeeda, H., Yeh, J., & Zalipsky, S. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-1547 · Cited by 97
Schnyder, A., Krähenbühl, S., Drewe, J., & Huwyler, J. (2005) · Journal of drug targeting · doi:10.1080/10611860500206674 · Cited by 95
Self-citationEarly cessation of the clinical development of LiPlaCis, a liposomal cisplatin formulation
de Jonge, M. J. A., Slingerland, M., Loos, W. J., Wiemer, E. A. C., Burger, H., Mathijssen, R. H. J., Kroep, J. R., den Hollander, M., van der Biessen, D. A. J., Lam, M.-H., et al. (2010) · European Journal of Cancer · doi:10.1016/j.ejca.2010.07.015 · Cited by 92
Ross, R. W., Zietman, A. L., Xie, W., Coen, J. J., Dahl, D. M., Shipley, W. U., Kaufman, D. S., Islam, T., Guimarães, A. R., Weissleder, R., et al. (2009) · Clinical Imaging · doi:10.1016/j.clinimag.2009.01.013 · Cited by 91
Dritschilo, A., Huang, C. H., Rudin, C. M., Marshall, J. L., Collins, B., Dul, J. L., Zhang, C., Kumar, D., Gokhale, P. C., Ahmad, A., et al. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-1260 · Cited by 91
Tolcher, A. W., Rodrigueza, W. V., Rasco, D. W., Patnaik, A., Papadopoulos, K. P., Amaya, A., Moore, T. D., Gaylor, S. K., Bisgaier, C. L., Sooch, M., et al. (2013) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-013-2361-0 · Cited by 89
Fan, H. Z., Hu, Q., Xu, F., Liang, W., Tang, G., & Yang, W. (2011) · Biomaterials · doi:10.1016/j.biomaterials.2011.10.043 · Cited by 89
Cited by
Nano based drug delivery systems: recent developments and future prospects
Patra, J. K., Das, G., Fraceto, L. F., Campos, E. V. R., Rodriguez-Torres, M. D. P., Acosta-Torres, L. S., Diaz-Torres, L. A., Grillo, R., Swamy, M. K., Sharma, S., et al. (2018) · Journal of Nanobiotechnology · doi:10.1186/s12951-018-0392-8 · Cited by 6,684
Zhang, X.-F., Liu, Z.-G., Shen, W., & Gurunathan, S. (2016) · International Journal of Molecular Sciences · doi:10.3390/ijms17091534 · Cited by 3,220
Liposomal Formulations in Clinical Use: An Updated Review
Bulbake, U., Doppalapudi, S., Kommineni, N., & Khan, W. (2017) · Pharmaceutics · doi:10.3390/pharmaceutics9020012 · Cited by 2,156
Ulbrich, K., Holá, K., Šubr, V., Bakandritsos, A., Tuček, J., & Zbořil, R. (2016) · Chemical Reviews · doi:10.1021/acs.chemrev.5b00589 · Cited by 1,730
Block copolymer micelles in nanomedicine applications
Cabral, H., Miyata, K., Osada, K., & Kataoka, K. (2018) · Chemical Reviews · doi:10.1021/acs.chemrev.8b00199 · Cited by 1,309
Metadata
- Authors
- Wicki, A., Witzigmann, D., Balasubramanian, V., & Huwyler, J.
- Venue
- Journal of Controlled Release
- Publisher
- Elsevier BV
- Published
- 2015-02
- Volume
- 200
- Pages
- 138-157
- ISSN
- 0168-3659 (ISSN-L)
- OpenAlex
- W2013765163
- Cited by
- 1,901
- References
- 248
- FWCI
- 43.26
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.